Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963779 | 0.95 | CYP1A2 (0.43) | CYP1A2SIGMAR1SMN1; SMN2FKBP1AEPHX1 | |
| SCHEMBL21152372 | 0.93 | CYP1A2 (0.46) | CYP1A2SIGMAR1SMN1; SMN2FKBP1AEPHX1 | |
| SCHEMBL19852059 | 0.91 | SIGMAR1 (0.47) | CYP1A2SIGMAR1FKBP1AEPHX1NAAA | |
| SCHEMBL21104963 | 0.91 | SIGMAR1 (0.47) | CYP1A2SIGMAR1FKBP1AEPHX1NAAA | |
| SCHEMBL13963782 | 0.91 | CYP1A2 (0.36) | CYP1A2SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13963780 | 0.86 | CYP1A2 (0.41) | CYP1A2SIGMAR1SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL11993528 | 0.84 | CYP1A2 (0.44) | CYP1A2SIGMAR1SMN1; SMN2FKBP1AEPHX1 | |
| SCHEMBL7426671 | 0.82 | HRH3 (0.41) | CYP1A2HRH3NAAA | |
| SCHEMBL13963781 | 0.81 | CYP1A2 (0.36) | CYP1A2SIGMAR1ALDH1A1 | |
| SCHEMBL7418924 | 0.81 | GNAO1 (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | CYP1A2 2958/4885SIGMAR1 3983/4885SMN1; SMN2 2231/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | CYP1A2 615/4885SIGMAR1 786/4885SMN1; SMN2 504/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | CYP1A2 2958/4885SIGMAR1 3983/4885SMN1; SMN2 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.